[Pathogenetic correction of reproductive function disorder in patients with normogonadotropic ovary deficiency caused by body mass deficiency].
The aim of the article was the recovery of fertility and realization of reproductive function of women with body mass deficiency (BMD). Thirty seven patients with normogonadotropic ovary deficiency caused by body mass deficiency (12-15% of normal value) underwent pathogenetic treatment, starting from the disorder of hypothalamic-hypophyseal-ovarian system. Pathogenetic therapy was directed to compensate body mass deficit. Hormonal replacement therapy aimed to restore the negative feedback. Compensation of body mass (5-7%) increases the efficiency of hormonal replacement therapy by 16% on average, while the total compensation of the deficiency is manifested in 68% cases of recovery. As a result of therapy, seven women with BMD restored fertility and realized their reproductive function.
Tokhunts
K A
KA
D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D015992:Body Mass Index; D004338:Drug Combinations; D004394:Dydrogesterone / Q000627:therapeutic use*; D004614:Emaciation / Q000453:epidemiology*; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D006062:Gonadotropins / Q000378:metabolism*; D006801:Humans; D007247:Infertility, Female / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D016912:Levonorgestrel / Q000627:therapeutic use*; D016649:Primary Ovarian Insufficiency / Q000453:epidemiology* / Q000503:physiopathology*
D004338:Drug Combinations; D006062:Gonadotropins; C472241:femoston; C097275:klimonorm; D004958:Estradiol; D016912:Levonorgestrel; D004394:Dydrogesterone